Celcuity Inc - Kewajiban jangka dawa perusahaan CELC

Celcuity Inc. revenues are based on the commercialization of the CELsignia system and gedatolisib for breast cancer therapy. The trend of the business's long-term debt clearly illustrates the financial leverage, where the value of 0.00 records this metric. Primary threats are linked to potential clinical trial failures, although current liquidity reserves minimize the risks of dependence on a single molecule.

Long-term debt measures the total volume of obligations with a maturity of more than one year, allowing for an assessment of financial leverage and capital structure stability when calculating the debt load. By analyzing the time series of the organization's long-term financial debt, an investor can compare borrowing rates with Celcuity Inc. (CELC) expenditures on the development of diagnostic IT systems and oncology drug research to minimize strategic risks.